Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New drug formulation approved for insomnia in older patients

  • Comment
Prescribers can now offer a melatonin on prescription to treat older adult patients diagnosed with primary insomnia.

Circadin is the first pharmaceutical grade licensed melatonin available for the short-term treatment of primary insomnia in patients aged 55 years or over. It is a prolonged-release formulation of synthesised melatonin that is released over several hours.

The drug is effective within three weeks of dosing, and helps to induce and maintain sleep, according to its developer Lundbeck. It will be available as a 21-day short course treatment.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs